Roche launches new lung, bladder cancer drug in India
Roche says Tecentriq has been approved in India for two types of cancers—non-small cell lung cancer (NSCLC) and urothelial carcinoma, a type of bladder and urinary tract cancer
New Delhi: Global pharma major Roche on Wednesday said it has launched monoclonal antibody atezolizumab under the brand name Tecentriq in India for treatment of lung and bladder cancer.
Tecentriq has shown to extend survival and improve the quality of life in the approved indications, Roche said in a statement. The product has been approved in India “for two types of cancers: non-small cell lung cancer (NSCLC) and urothelial carcinoma, a type of bladder and urinary tract cancer”, it added.
The drug will now be available to patients in India on the prescription of oncologists, Roche said. Commenting on the development, Roche Products India Pvt. Ltd managing director Lara Bezerra said: “Bringing Tecentriq to India reflects Roche’s commitment to bring global innovations to the country.”
The company believes that Tecentriq will play an important role in the treatment of people with advanced bladder cancer and metastatic non-small cell lung cancer in India, she added.
“Roche has helped transform the treatment of cancer globally, and will continue to set newer standards of care for cancer patients in India,” Bezerra said. Tecentriq is a monoclonal antibody used for treatment of metastatic non-small cell lung cancer and metastatic urothelial carcinoma. It is a cancer immunotherapy drug that is designed to work with body’s natural defence system.
- Solar tariffs touch Rs 2.59 per unit in NTPC’s tender
- RIL, BP spend over ₹7,000 crore to prolong output from gas fields in KG basin
- India reviews draft e-commerce policy after criticism
- Cosmos Bank’s server hacked, ₹ 94 crore siphoned off in 2 days
- NIO seeks to raise $1.8 billion in biggest US listing by China automaker
Editor's Picks »
- BofA-ML survey: Short EM equity second most crowded trade
- GST-led shift from informal to formal sector happening, but at a snail’s pace
- Uncertain earnings for agricultural input firms despite bountiful rains
- PVR pays a premium for south
- Tata Steel’s Q1 supports India push but investors enquire at what cost